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Introduction: Homologous recombination (HR) DNA repair is of clinical relevance in breast cancer. Three DNA-
based homologous recombination deficiency (HRD) scores (HRD-loss of heterozygosity score (LOH), HRD-telomeric
allelic imbalance score (TAI), and HRD-large-scale state transition score (LST)) have been developed that are highly
correlated with defects in BRCA1/2, and are associated with response to platinum therapy in triple negative breast
and ovarian cancer. This study examines the frequency of BRCA1/2 defects among different breast cancer subtypes,
and the ability of the HRD scores to identify breast tumors with defects in the homologous recombination DNA
repair pathway.
Methods: 215 breast tumors representing all ER/HER2 subtypes were obtained from commercial vendors. Next-
generation sequencing based assays were used to generate genome wide SNP profiles, BRCA1/2 mutation screening,
and BRCA1 promoter methylation data.
Results: BRCA1/2 deleterious mutations were observed in all breast cancer subtypes. BRCA1 promoter methylation was
observed almost exclusively in triple negative breast cancer. BRCA1/2 deficient tumors were identified with BRCA1/2
mutations, or BRCA1 promoter methylation, and loss of the second allele of the affected gene. All three HRD scores were
highly associated with BRCA1/2 deficiency (HRD-LOH: P = 1.3 × 10-17; HRD-TAI: P = 1.5 × 10-19; HRD-LST: P = 3.5 × 10-18). A
combined score (HRD-mean) was calculated using the arithmetic mean of the three scores. In multivariable analyses the
HRD-mean score captured significant BRCA1/2 deficiency information not captured by the three individual scores, or by
clinical variables (P values for HRD-Mean adjusted for HRD-LOH: P = 1.4 × 10-8; HRD-TAI: P = 2.9 × 10-7; HRD-LST: P = 2.8 ×
10-8; clinical variables: P = 1.2 × 10-16).
Conclusions: The HRD scores showed strong correlation with BRCA1/2 deficiency regardless of breast cancer subtype.
The frequency of elevated scores suggests that a significant proportion of all breast tumor subtypes may carry defects in
the homologous recombination DNA repair pathway. The HRD scores can be combined to produce a more robust
predictor of HRD. The combination of a robust score, and the FFPE compatible assay described in this study, may
facilitate use of agents targeting homologous recombination DNA repair in the clinical setting.* Correspondence: ktimms@myriad.com
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Defects in genes in the homologous recombination (HR)
pathway are of potential therapeutic relevance in a variety
of cancers. Clinical studies have demonstrated that BRCA1/
2-deficient tumors are sensitive to both platinum salts and
poly(ADP-ribose) polymerase inhibitors [1,2]. BRCA1/2 de-
ficiency is known to be a result of deleterious germline or
somatic mutations, or methylation of the BRCA1 promoter.
Numerous studies have investigated the rate of BRCA1/2
mutations in triple-negative breast cancer (TNBC), with re-
ported mutation rates ranging from 10 to 40% in this breast
cancer subtype [3-8]. Many of these studies, however, fo-
cused on select patient populations known to be enriched
for BRCA1/2 mutations. Methylation of the BRCA1 pro-
moter and associated loss of expression of the gene have
been reported in approximately 25% of breast cancers, with
the frequency in TNBC reported to be as high as 31% [9].
These studies suggest that the frequency of BRCA1/2 defi-
ciency in TNBC is between 45 and 70%. In light of this,
current clinical studies are focused on investigating TNBC
for response to agents that are believed to exploit HR de-
fects, including platinum agents and poly (ADP-ribose)
polymerase inhibitors.
Genomic instability as a consequence of double-
stranded DNA repair deficiency is a hallmark of TNBC
[10]. Recently, three quantitative metrics accurately
reflecting this genomic instability have been developed,
namely whole genome tumor loss of heterozygosity
profiles (homologous recombination deficiency–loss
of heterozygosity (HRD-LOH) score) [11], telomeric
allelic imbalance (homologous recombination defi-
ciency–telomeric allelic imbalance (HRD-TAI) score)
[12], and large-scale state transitions (homologous
recombination deficiency– large-scale state transition
(HRD-LST) score) [13] All three scores are highly cor-
related with defects in BRCA1/2 and other HR pathway
genes in breast cancer or ovarian cancer, and are associ-
ated with sensitivity to platinum agents [11-14].
While the role of BRCA1/2 defects has been well studied
in TNBC, significantly less information is available for
other breast cancer subtypes. Even less is known about the
proportion of non-TNBC tumors with elevated HRD-
LOH, HRD-TAI, or HRD-LST scores reflecting loss of
double-stranded DNA break repair capacity. This study
examines the frequency of BRCA1/2 defects and elevated
scores across breast cancer subtypes, and examines the as-
sociation of the HRD-LOH, HRD-TAI, and HRD-LST
scores with BRCA1/2 deficiency in breast tumors.
We also report the development of a next-generation
sequencing-based assay that can be used to calculate all
three scores, and is compatible with DNA extracted
from formalin-fixed paraffin-embedded (FFPE)-treated
tumor samples. Development of this assay should facili-
tate the use of these scores in the clinical setting.Materials and methods
Breast tumor samples
Two hundred and fifteen breast tumor samples, and
matched normal tissue blocks from the same patient, were
obtained from four commercial vendors (Asterand, Detroit,
MI, USA; ILSBio, Chestertown, MD, USA; ProteoGenex,
Culver City, CA, USA; Indivumed, Hamburg, Germany).
Samples were selected at random from the inventory list
provided by each vendor, with the exception that attempts
were made to balance the number of samples from
each breast cancer subtype as defined by estrogen receptor
(ER) and tyrosine kinase-type cell surface receptor HER2
status (triple-negative, n = 63; ER+/HER2–, n = 51; ER–/
HER2+, n = 38; ER+/HER2+, n = 63). The vendors provided
the results of immunohistochemistry ER and HER2 ana-
lysis. All samples were obtained under Institutional Review
Board-approved protocols. Patient and tumor characteris-
tics are shown in Tables S1 and S2 in Additional file 1.
Extraction of DNA from frozen tumors
A 5 μm hematoxylin and eosin slide was created and
reviewed by a pathologist to facilitate enrichment of
tumor-derived DNA. Frozen 10 μm sections were cut and
the regions of highest tumor cell density were scraped
from the slide. The Promega Maxwell 16 LEV Blood DNA
kit (AS1290; Promega, Madison, WI, USA) was used to
extract DNA. Tissue samples were incubated overnight at
56°C with proteinase K and lysis buffer in a shaking heat
block. After the overnight incubation, undigested material
was spun out and the Maxwell cartridges were loaded.
Genomic DNA was eluted in 60 μl water.
Promoter methylation quantitative PCR assays
The Methyl-Profiler DNA Methylation PCR Assay System
(SABiosciences, Valencia, CA, USA) was used to quantify
methylation levels. The assay was performed as per the
manufacturer’s recommended protocol. A description of
the assay is provided in [11].
Hybridization capture and sequencing
A custom enrichment panel was developed that targeted
54,091 single nucleotide polymorphisms (SNPs) distributed
across the complete human genome (Agilent Technologies,
Santa Clara, CA, USA). A detailed description of the panel
design and development is provided in Materials and
Methods in Additional file 1. The final panel also included
an additional 685 probes targeting the complete coding
region of BRCA1 and BRCA2. A detailed description of the
assay process is also provided in Materials and Methods in
Additional file 1.
BRCA1 and BRCA2 mutation screening
Variant and large rearrangement detection was per-
formed on sequences from BRCA1 and BRCA2. Complete
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tection methods are provided in Materials and Methods in
Additional file 1.
Mutations identified were only included in the analysis
if classified as deleterious or suspected deleterious based
on previously described criteria [15].
Calculation of HRD-LOH, HRD-TAI, and HRD-LST scores
The allele specific copy number at each SNP location was
determined using an algorithm described in [11]. Descrip-
tions of the homologous recombination deficiency (HRD)
scores are provided in Materials and Methods in Additional
file 1.
Selection of samples for statistical analysis
Eighteen of 215 samples were excluded from the statis-
tical analysis due to either high levels of contamination
with noncancerous cells and/or low-quality SNP data
(Materials and Methods in Additional file 1).
Statistical analysis
Descriptions of the statistical analyses performed are
provided in Materials and Methods in Additional file 1.
Results
Frequency of BRCA1/2 defects
BRCA1 and BRCA2 sequence data were used to screen
for both somatic and germline deleterious mutations. The
analysis included detection of short variants and longer
rearrangements spanning up to multiple exons in length.
Variant analysis was successfully performed on 100% of
samples, while large rearrangement analysis proved less ro-
bust, with 167/215 samples producing data that passed the
quality control metrics for this assay. Deleterious muta-
tions were observed in 25/215 individuals. Subsequently,
DNA extracted from matching normal tissue samples from
24 out of the 25 individuals was used to determine whether
the mutations found were germline or somatic. Four of the
mutation carriers (16%) had multiple deleterious variants.
Sequencing of matched normal DNA from these patients
confirmed that each patient carried only one germline
deleterious mutation and therefore the additional muta-
tions in these individuals were somatic. In those individuals
with a single deleterious mutation, loss of heterozygosity
was observed at the affected gene in all but one individual.
One individual was identified who carried a somatic
BRCA1 deleterious mutation (Y1522X) in one allele; this
individual had a total of three copies of BRCA1, two of
which appeared to be fully functional. Therefore, for the
purposes of further analysis we classified this individual as
BRCA1/2 intact. Results of the mutation screening analysis
are shown in Tables S3 and S4 in Additional file 1.
As expected, the highest rates of BRCA1/2 mutations
were observed in triple-negative tumors (15.9%). In oneTNBC patient, the only BRCA1 mutation was somatic;
the other six individuals with a single deleterious muta-
tion all carried germline mutations. Normal tissue DNA
was not available for one TNBC patient carrying a dele-
tion of one exon in BRCA1 in their tumor sample. Con-
sequently, it was not possible to determine whether
this deleterious mutation was a germline mutation or a
somatic mutation. Two additional TNBC tumors carried
both germline and somatic mutations. BRCA1/2 muta-
tions were detected in all three of the other breast can-
cer subtypes with frequencies ranging from 7.8 to 11.1%
(Table S3 in Additional file 1). The fraction of somatic
mutations observed in these subtypes ranged from 0 to
50%; however, the total number of mutants was too low
to obtain a reliable estimate of the frequency of germline
versus somatic BRCA1/2 mutations in the different
subtypes.
Significant rates of BRCA1 promoter methylation have
been reported in triple-negative breast tumors. In this
dataset, BRCA1 promoter methylation was found almost
exclusively in triple-negative tumors. Twenty-one per-
cent of the triple-negative tumors showed significant
levels of methylation of the BRCA1 promoter, compared
with <2% in each of the other breast cancer subtypes
(Table S3 in Additional file 1). All tumors with BRCA1
promoter methylation had confirmed loss of the second
allele by loss of heterozygosity.
HRD-LOH, HRD-TAI, and HRD-LST scores across breast
cancer subtypes and association with BRCA1/2 deficiency
A custom Agilent SureSelect hybridization enrichment
assay was developed to enable the generation of high-
quality copy number and allele dosage data from low-yield,
low-quality FFPE-treated tumor samples. The development
of this assay is described in detail in Materials and Methods
in Additional file 1. Improved performance of the SNP se-
quencing assay on both frozen and FFPE tumor samples
compared with SNP microarray data is shown in Additional
file 2. SNP data were used to calculate HRD-LOH, HRD-
TAI, and HRD-LST scores. One hundred and ninety-seven
of 215 samples gave scores that passed the quality control
criteria used. Thirty-eight of these samples were BRCA1/2
deficient. In univariate logistic regression analysis, each
of the HRD scores (HRD-LOH, HRD-TAI, and HRD-
LST) was significantly associated with BRCA1/2 deficiency
(Table 1). Univariate results for age at diagnosis, breast
cancer subtype, and tumor grade (both categorical and
numeric) were also statistically significant (Table 1). Can-
cer stage was not associated with BRCA1/2 status.
Fifty-two of 197 samples were from TNBC samples, in-
cluding 23 that were BRCA1/2 deficient. Each of the HRD
scores was significantly associated with BRCA1/2 defi-
ciency in this breast cancer subtype (Table S5 in Additional
file 1). When the same analysis was performed for each
Table 1 Results from univariate logistic regression with HRD scores or clinical variables as predictors of BRCA1/2
deficiency
Number of patients Number BRCA1/2 deficient P value OR (95% CI)
HRD-LOH score 197 38 1.3 × 10-17 22 (8.4, 58)
HRD-TAI score 197 38 1.5 × 10-19 17 (7.2, 41)
HRD-LST score 197 38 3.5 × 10-18 19 (7.7, 46)
HRD-mean score 197 38 1.1 × 10-24 90 (22, 360)
Age at diagnosis 196 37 0.0071 0.96 (0.94, 0.99)
Stage 0.88
I 13 3 1
II 121 23 0.78 (0.2, 3.1)
III 54 9 0.67 (0.15, 2.9)
IV 3 1 1.7 (0.11, 25)
Cancer subtype 1.2 × 10-5
TNBC 52 23 8.5 (2.3, 31)
ER–/HER2+ 35 3 1
ER+/HER2– 50 5 1.2 (0.26, 5.3)
ER+/HER2+ 60 7 1.4 (0.34, 5.8)
Gradea (categorical) 0.0011 NA
1 17 0 1
2 102 14 ∞ (0, ∞)
3 71 21 ∞ (0, ∞)
Grade (numerical) 0.00053 3.1 (1.6, 6.3)
Odds ratios for HRD scores are reported per interquartile range of the score. The odds ratio for age is reported per year. The odds ratio for grade (numerical) is
per unit. CI, confidence interval; ER, estrogen receptor; HER2, tyrosine kinase-type cell surface receptor HER2; HRD, homologous recombination deficiency; HRD-
LOH, homologous recombination deficiency-loss of heterozygosity; HRD-LST, homologous recombination deficiency-large-scale state transition; HRD-Mean, mean
of the three HRD scores; HRD-TAI, homologous recombination deficiency-telomeric allelic imbalance; NA, not available; OR, odds ratio; TNBC, triple-negative breast
cancer. aThe odds ratio for categorical grade is inestimable due to zero BRCA1/2-deficient grade 1 tumors.
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for all scores except in the ER–/HER2+ subtype (Table
S5 in Additional file 1). The distribution of scores is
shown for BRCA1/2-deficient versus BRCA1/2-intact
samples in Figure 1. High HRD scores were observed in
BRCA1/2-intact tumors, in addition to BRCA1/2-defi-
cient tumors, suggesting that a subset of these tumors
have HR deficiency via some alternate mechanism.
Pairwise correlations of the HRD-LOH, HRD-TAI, and
HRD-LST scores were examined graphically, and quanti-
fied with Spearman rank-sum correlation. All pairwise
correlations of scores showed positive correlation signifi-
cantly different from zero (P < 10-16) (Figure 2).
Table 2 presents the results of a three-term multivariable
logistic regression including HRD-LOH, HRD-TAI, and
HRD-LST scores as predictors of BRCA1/2 deficiency. In
this analysis, both HRD-TAI (P = 0.00016) and HRD-
LST (P = 0.00014) scores captured significant BRCA1/2
deficiency information independent of the other scores.
The HRD-LOH score did not reach statistical signifi-
cance (P = 0.069).
Since each of the HRD measures appears to offer
additional information that could be potentially clinicallyuseful, we explored the utility of combining the three
scores. Our first approach was to combine the HRD scores
according to the best linear combination from a logistic
regression model to predict BRCA1/2 deficiency in this
dataset. The resulting model-based score was:
HRD‐model ¼ 0:11xHRD‐LOH þ 0:25xHRD‐TAI
þ 0:12xHRD‐LST
A disadvantage of this approach is that the optimal
weights for individual HRD scores are overfitted because
of the relatively small size of the dataset and moderate
correlations between the scores.
An alternate approach is to consider a simple arith-
metic mean of the three scores (HRD-Mean score). A ra-
tionale for averaging the scores is that all three scores
essentially count events, breakpoints, or regions between
breakpoints associated with HR deficiency. Moreover,
according to univariate association of the scores with
BRCA1/2 deficiency (Table 1), they seem to capture rele-
vant events equally well.
To assess whether the HRD-Mean score adequately cap-
tured the BRCA1/2 deficiency information of its three
Figure 1 Distribution of scores in BRCA1/2-intact and BRCA1/2-deficient samples. (A) Homologous recombination deficiency-loss of hetero-
zygosity (HRD-LOH) score. (B) Homologous recombination deficiency-telomeric allelic imbalance (HRD-TAI) score. (C) Homologous recombination
deficiency-large-scale state transition (HRD-LST) score. (D) Mean of the homologous recombination deficiency (HRD-Mean) score. Red bars,
BRCA1/2-intact samples; blue bars, BRCA1/2-deficient samples.
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models. Each included the HRD-Mean score and one of
the three individual scores. None of the component scores
added significantly to the HRD-Mean score at the 5% sig-
nificance level (HRD-LOH, P = 0.89; HRD-TAI, P = 0.09;
HRD-LST, P = 0.28). In contrast, in each of the bivariate
models’ HRD-Mean score added significant informationto the individual scores (P = 1.4 × 10-8 for HRD-LOH;
P = 2.9 × 10-7 for HRD-TAI; P = 2.8 × 10-8 for HRD-LST).
The HRD-Mean score was also compared with the
HRD model score. In a bivariate logistic regression
model, the HRD model score did not add significant in-
dependent BRCA1/2 deficiency information to the HRD-
Mean score (P = 0.089).
Figure 2 Spearman correlation of three different homologous recombination deficiency scores. Panels above the diagonal show
correlation. Diagonal panels show density plots. HRD-LOH, homologous recombination deficiency-loss of heterozygosity; HRD-LST, homologous
recombination deficiency-large-scale state transition; HRD-TAI, homologous recombination deficiency-telomeric allelic imbalance.
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were available for the majority of samples (Table S1 in
Additional file 1). Associations of these clinical variables
with the HRD-Mean score are shown in Figure 3. The
HRD-Mean score was not significantly correlated with
tumor stage or age at diagnosis at the 5% confidence level,Table 2 Results from a three-term multivariable logistic
regression model with HRD-LOH, HRD-TAI, and HRD-LST
scores as predictors of BRCA1/2 deficiency
Score P value OR (95% CI)
HRD-LOH 0.069 3.0 (0.89, 9.8)
HRD-TAI 0.00016 5.8 (2.1, 16)
HRD-LST 0.00014 7.4 (2.4, 23)
Odds ratios are reported per interquartile range. This analysis included 197
patients, 38 of whom were BRCA1 or BRCA2 deficient. CI, confidence interval;
HRD-LOH, homologous recombination deficiency-loss of heterozygosity;
HRD-LST, homologous recombination deficiency-large-scale state transition;
HRD-TAI, homologous recombination deficiency-telomeric allelic imbalance;
OR, odds ratio.but there was significant correlation with tumor grade
(Spearman correlation 0.23, P = 0.0017). The HRD-Mean
score also differed significantly among breast cancer sub-
types (P = 1.6 × 10-5) according to a Kruskal–Wallis one-
way analysis of variance test.
Heterogeneity of the HRD-Mean score among clinical
breast cancer subpopulations was examined in multivari-
able logistic regression models. For each clinical variable
we added a term for the interaction with the HRD-Mean
score to a model including all clinical variables and the
HRD-Mean score. None of the interaction terms reached
significance at the 5% significance level. We therefore
found no evidence to suggest that the probability of
BRCA1/2 deficiency conferred by the HRD-Mean score
varies among clinical subpopulations.
Multivariable analysis was used to examine a model
based on the HRD-Mean score and all available clinical
variables. The HRD-Mean score captured significant
BRCA1/2 deficiency information that was not captured by
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Figure 3 Association of clinical variables with the HRD-Mean score. Upper left panel: tumor grade; upper right panel: tumor stage; lower left
panel: tumor IHC subtype; lower right panel: age at diagnosis. Mean of the homologous recombination deficiency-loss of heterozygosity, homologous
recombination deficiency-large-scale state transition, and homologous recombination deficiency-telomeric allelic imbalance scores (HRD-Mean score).
ER, estrogen receptor; HER2, tyrosine kinase-type cell surface receptor HER2; HRD, homologous recombination deficiency; TNBC, triple-negative
breast cancer.
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the multivariable setting (P = 0.027) (Table 3).
To assess the robustness of the hybridization enrichment
assay, 42 samples were run in duplicate. Both sets of data
were analyzed separately in a blinded analysis. The Pearson
correlation coefficient was 0.89 for the HRD-LOH score,
0.92 for the HRD-TAI score, 0.84 for the HRD-LST score,
and 0.93 for the HRD-Mean score (Additional file 3).
Discussion
Defects in homologous recombination, including BRCA1/
2 defects, are a relatively frequent event in TNBC, and the
exploitation of these defects in the clinical setting is under
intensive study. Less is known about the frequency of
homologous recombination defects in other subtypes of
breast cancer. In this study, the frequency of BRCA1/2
mutations ranged from ~8 to ~16% across four subtypes
of breast cancer as defined by immunohistochemistry sub-
typing. Sequencing of matched tumor and normal DNA
samples determined that 75% of BRCA1/2 mutant tumorscarried a germline BRCA1/2 mutation. The most common
method for loss of the second allele was via loss of hetero-
zygosity; however, 17% of the tumors did not have loss of
heterozygosity but carried somatic deleterious mutations
in addition to their germline mutation. In addition, an ap-
parently sporadic breast tumor was seen in one individual
carrying a BRCA2 somatic deleterious mutation. BRCA1/2
deficiency, including deleterious mutations and BRCA1
promoter methylation, ranged from ~10 to ~37% across
the four subtypes.
Three independent studies recently reported the devel-
opment of DNA-based genomic scores that were associ-
ated with defects in BRCA1/2 [11-13]. In addition, all
three scores have been shown to either predict sensitivity
to platinum drugs in vitro, and/or pathologic response to
neoadjuvant platinum treatment [12-14].
All three scores showed strong correlation with
BRCA1/2 deficiency regardless of subtype, and the fre-
quency of elevated scores suggests that a significant pro-
portion of all breast tumor subtypes carry defects in the
Table 3 Results from multivariable logistic regression of BRCA1/2 deficiency
Number of patients Number BRCA1/2 deficient P value OR (95% CI)
HRD-Mean score 186 34 1.2 × 10-16 87 (17, 450)
Age at diagnosis 186 34 0.027 0.95 (0.91, 1.0)
Stage 0.63
I 12 3 1
II 119 22 2.4 (0.22, 27)
III 52 8 0.99 (0.073, 13)
IV 3 1 3.1 (0.0011, 9100)
Gradea 0.40
1 17 0 1
2 99 14 ∞ (0, ∞)
3 70 20 ∞ (0, ∞)
Subtype 0.087
TNBC 44 19 3.9 (0.62, 24)
ER–/HER2+ 34 3 1
ER+/HER2– 48 5 0.39 (0.039, 3.8)
ER+/HER2+ 60 7 1.3 (0.16, 10)
Odds ratio for the HRD-Mean score is reported per interquartile range of the score. The odds ratio for age at diagnosis is reported per year. This analysis includes
186 patients with complete clinical records. Thirty-four patients were BRCA1 or BRCA2 deficient. CI, confidence interval; ER, estrogen receptor; HER2, tyrosine
kinase-type cell surface receptor HER2; HRD-Mean, mean of the homologous recombination deficiency-loss of heterozygosity, homologous recombination
deficiency-large-scale state transition, and homologous recombination deficiency-telomeric allelic imbalance scores; OR, odds ratio; TNBC, triple-negative breast
cancer. aThe odds ratio for grade is inestimable due to zero BRCA1/2-deficient grade 1 tumors.
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findings suggest that agents which target or exploit
DNA damage repair may prove effective across a subset
of tumors from all subtypes of breast cancer.
All three scores were significantly correlated with one
another, suggesting that they all measure the same core
genomic phenomenon. However, logistic regression ana-
lysis indicates that the scores could be combined result-
ing in stronger association with BRCA1/2 deficiency in
this dataset. Further study is required to define a robust
optimal model for response to clinical agents in an ad-
equately powered dataset. In this study, an optimized
model (HRD model) did not capture additional BRCA1/
2 deficiency information when compared with the arith-
metic mean (HRD-Mean score) of the three scores.
Implementation of these scores, either singly or in
combination, in the clinical setting requires an assay that
is compatible with core needle biopsies that have been
formalin fixed and paraffin embedded. Samples of this
type yield very low-quantity and low-quality DNA. DNA
extracted from these FFPE-treated samples does not per-
form well in SNP microarray analysis.
Liquid hybridization-based target enrichment tech-
nologies have been developed for production of libraries
for next-generation sequencing. These methodologies
enable targeted sequencing of regions of interest after
reduction in genomic complexity, resulting in decreased
sequencing costs. Preliminary tests indicated that theavailable assays should be compatible with DNA derived
from FFPE DNA. In this study we report the develop-
ment of a capture panel that targets ~54,000 SNPs dis-
tributed across the genome. Allele counts from the
sequencing information this panel provides can be used
for copy number and loss of heterozygosity reconstruc-
tion, and the calculation of all three of the HRD scores.
In addition, BRCA1 and BRCA2 capture probes are in-
cluded on the panel, which enable high-quality mutation
screening for deleterious variants in these genes in the
same assay.Conclusions
BRCA1/2 mutations are most common in TNBC; how-
ever, both germline and somatic mutations were observed
in all subtypes of breast cancer. In contrast, BRCA1 pro-
moter methylation was confined almost exclusively to
TNBC. Elevated HRD scores were highly associated with
BRCA1/2 deficiency regardless of breast cancer subtype,
and the most robust predictor of HRD deficiency is likely
to be a combination of all three individual HRD scores.
The combination of a robust score capable of identifying
tumors with defects in homologous recombination DNA
repair, and an assay compatible with FFPE clinical patho-
logical specimens should facilitate the development and use
of agents targeting double-stranded DNA damage repair in
the clinical setting. In addition, these data suggest that such
Timms et al. Breast Cancer Research  (2014) 16:475 Page 9 of 9agents may have utility across all subtypes of breast cancer
when combined with an appropriate biomarker.
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